Investment Analysts’ Recent Ratings Changes for Intercept Pharmaceuticals (ICPT)

Several brokerages have updated their recommendations and price targets on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) in the last few weeks:

  • 12/2/2019 – Intercept Pharmaceuticals is now covered by analysts at Canaccord Genuity. They set a “buy” rating on the stock.
  • 11/25/2019 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Robert W. Baird. They now have a $227.00 price target on the stock.
  • 11/25/2019 – Intercept Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $86.00 to $102.00.
  • 11/23/2019 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 11/5/2019 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Wedbush. They now have a $243.00 price target on the stock.
  • 11/5/2019 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $150.00 price target on the stock.
  • 10/31/2019 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/21/2019 – Intercept Pharmaceuticals had its price target lowered by analysts at Raymond James from $148.00 to $147.00. They now have a “strong-buy” rating on the stock.
  • 10/18/2019 – Intercept Pharmaceuticals was given a new $125.00 price target on by analysts at Jefferies Financial Group Inc. They now have a “buy” rating on the stock.
  • 10/18/2019 – Intercept Pharmaceuticals had its price target lowered by analysts at Credit Suisse Group AG from $167.00 to $87.00.
  • 10/16/2019 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/14/2019 – Intercept Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. They now have a $63.00 price target on the stock. According to Zacks, “Intercept’s lead drug Ocaliva’s performance has been strong in the year so far. Management’s efforts to increase awareness about the label update of the drug in 2018 and expand sales force across the United States, thereafter, are yielding results. Solid growth in patient enrollment is likely to drive the company’s performance. Meanwhile, Intercept is working to expand the drug’s label in the promising NASH space. While the failure of Gilead’s late-stage study on selonsertib in patients suffering from compensated cirrhosis due to NASH puts Intercept ahead in the race, additional results from the REGENERATE study in NASH were mixed and did not impress investors. Nevertheless, a potential approval in this indication will significantly boost growth. However, shares have underperformed the industry in the year so far.”
  • 10/10/2019 – Intercept Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Intercept Pharmaceuticals stock traded up $3.74 during trading hours on Wednesday, hitting $117.64. The stock had a trading volume of 729,968 shares, compared to its average volume of 740,264. The company has a 50-day moving average of $81.90 and a two-hundred day moving average of $74.08. The company has a quick ratio of 5.49, a current ratio of 5.49 and a debt-to-equity ratio of 4.02. The company has a market cap of $3.55 billion, a PE ratio of -10.83 and a beta of 1.44. Intercept Pharmaceuticals Inc has a fifty-two week low of $56.76 and a fifty-two week high of $131.87.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($2.59) EPS for the quarter, missing the consensus estimate of ($2.35) by ($0.24). The firm had revenue of $61.95 million during the quarter, compared to analyst estimates of $63.89 million. Intercept Pharmaceuticals had a negative net margin of 143.09% and a negative return on equity of 495.47%. The company’s revenue was up 31.8% on a year-over-year basis. During the same period last year, the company earned ($2.18) EPS. As a group, analysts forecast that Intercept Pharmaceuticals Inc will post -10.11 EPS for the current fiscal year.

In other Intercept Pharmaceuticals news, EVP Christian Weyer sold 4,373 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $100.00, for a total value of $437,300.00. Following the completion of the transaction, the executive vice president now owns 17,509 shares of the company’s stock, valued at approximately $1,750,900. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David A. Ford sold 800 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $70.00, for a total value of $56,000.00. Following the completion of the transaction, the insider now directly owns 11,546 shares of the company’s stock, valued at approximately $808,220. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,413 shares of company stock valued at $5,373,435. Insiders own 5.00% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co NY grew its stake in shares of Intercept Pharmaceuticals by 13.2% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 8,113 shares of the biopharmaceutical company’s stock valued at $538,000 after purchasing an additional 943 shares during the period. Man Group plc grew its stake in shares of Intercept Pharmaceuticals by 396.2% in the 3rd quarter. Man Group plc now owns 35,688 shares of the biopharmaceutical company’s stock valued at $2,368,000 after purchasing an additional 28,496 shares during the period. Orbimed Advisors LLC bought a new stake in shares of Intercept Pharmaceuticals in the 3rd quarter valued at approximately $2,137,000. Squarepoint Ops LLC bought a new stake in shares of Intercept Pharmaceuticals in the 3rd quarter valued at approximately $1,193,000. Finally, Voloridge Investment Management LLC bought a new stake in shares of Intercept Pharmaceuticals in the 3rd quarter valued at approximately $225,000. 79.67% of the stock is owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Story: What is a put option?

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.